<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004366</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00066548</org_study_id>
    <nct_id>NCT02004366</nct_id>
  </id_info>
  <brief_title>Linagliptin Inpatient Trial</brief_title>
  <official_title>Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, open label trial to compare the safety and efficacy
      of linagliptin (an oral anti diabetic medication) given orally once daily to an insulin
      regimen of glargine once daily plus rapid-acting insulin before meals. Both of these
      treatment groups will be given corrective doses of rapid-acting insulin analogs (aspart,
      lispro or glulisine) before meals if their blood sugars are &gt; 140 mg/dl.

      The patients will be monitored for their blood sugars while the hospital.

      If patients are agreeable to participate in the discharge part of the study, the
      investigators will randomized them to a treatment group based on their admission HbA1c. The
      investigators will follow these patients for 3 months with phone calls and clinic visits, and
      will monitor their blood sugars. This is to compare the efficacy of linagliptin and our
      discharge treatment algorithm in controlling blood sugars as out patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To determine whether in-hospital glycemic control, as measured by mean daily
      glucose concentration and frequency of hypoglycemic events, is different between treatment
      with linagliptin (Tradjenta®) plus correction doses with a rapid-acting insulin analog before
      meals and a basal bolus regimen with glargine once daily and rapid-acting insulin analog
      before meals in general surgery patients with T2D.

      Specific Aim 2: To determine the efficacy and safety of an A1C based discharge algorithm in
      controlling BG after discharge in patients with T2D. Patients who participate in the
      in-hospital arm (Aim 1) will be invited to enroll in this open label prospective outpatient
      study. The total duration of the study is 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Glycemic Control</measure>
    <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
    <description>Determine differences in glycemic control as measured by mean daily BG concentration between linagliptin alone and basal bolus therapy group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia &lt;70 mg/dl</measure>
    <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
    <description>Subjects with Hypoglycemia &lt;70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
    <description>Subjects with BG &gt; 300 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Dose of Insulin</measure>
    <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
    <description>Total daily dose of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>During Hospitalization</time_frame>
    <description>Length of hospital stay (ONLY for inpatient arms 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring ICU Care During Hospitalization</measure>
    <time_frame>During Hospitalization-average 5 days</time_frame>
    <description>Need for intensive care unit (ICU) care (transfer to ICU) during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Complications</measure>
    <time_frame>During Hospitalization-average 5 days</time_frame>
    <description>Subjects with composite complication (ONLY for inpatient arms 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Renal Failure During Hospitalization</measure>
    <time_frame>During Hospitalization-average 5 days</time_frame>
    <description>Subjects with Acute renal failure (ONLY for inpatient arms 1 and 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>During Hospitalization-average 5 days</time_frame>
    <description>Hospital mortality (ONLY in-patient). Mortality is defined as death occurring during hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting BG Concentration</measure>
    <time_frame>During Hospitalization (average 5 days) and outpatient up to 12 weeks</time_frame>
    <description>Average - per hospital stay - fasting BG concentration (for in-hospital groups), and average - per outpatient follow-up period - fasting BG concentration (for discharge groups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Wound and Other Infections</measure>
    <time_frame>During Hospitalization and outpatient up to 12 weeks</time_frame>
    <description>Subjects with wound and other infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Level</measure>
    <time_frame>Admission to the hospital and 12-week follow-up outpatient visit</time_frame>
    <description>HbA1c level at admission (for in-patient arms) and HbA1c level at 12-week follow-up outpatient visit (for discharge arms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia &lt; 40 mg/dl</measure>
    <time_frame>Inpatient and up to 12 weeks outpatient</time_frame>
    <description>Subjects with Hypoglycemia &lt; 40 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Room Visits</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Number of ER visits ONLY for outpatient arms 3,4, and 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Surgical Reinterventions</measure>
    <time_frame>Inpatient and up to 12 weeks outpatient</time_frame>
    <description>Subjects with surgical re-interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Mortality</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Deaths among patients after hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Linagliptin In-hospital</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin once daily+ correction doses of aspart or lispro if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal Bolus In-hospital</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin on discharge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin+50%Glargine dose on d/c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin+80%Glargine dose on d/c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
    <arm_group_label>Linagliptin In-hospital</arm_group_label>
    <other_name>Tradjenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal Bolus</intervention_name>
    <description>Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
    <arm_group_label>Basal Bolus In-hospital</arm_group_label>
    <other_name>Glargine (Lantus) + aspart (Novolog) or lispro (Humalog)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
    <arm_group_label>Linagliptin on discharge</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin + 50% Glargine dose on discharge</intervention_name>
    <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
    <arm_group_label>Linagliptin+50%Glargine dose on d/c</arm_group_label>
    <other_name>Trajenta, Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin + 80% Glargine</intervention_name>
    <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
    <arm_group_label>Linagliptin+80%Glargine dose on d/c</arm_group_label>
    <other_name>Trajenta, Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or female surgical non-ICU patients ages between18 and 80 years

          2. A known history of T2D &gt; 1 month, receiving either diet alone, oral antidiabetic
             agents: sulfonylureas and metformin as monotherapy or in combination therapy
             (excluding DPP-4 inhibitors) or low-dose (≤ 0.5 units/kg/day) insulin therapy.

          3. Subjects with a BG &gt;140 mg and &lt; 400 mg/dL at time of randomization without laboratory
             evidence of diabetic ketoacidosis (serum bicarbonate &lt; 18 mEq/L or positive serum or
             urinary ketones)

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 80 years.

          2. Subjects with increased BG concentration, but without a history of diabetes (stress
             hyperglycemia).

          3. Subjects with a history of type 1 diabetes (suggested by BMI &lt; 25 requiring insulin
             therapy or with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic
             state, or ketonuria) (43).

          4. Treatment with dipeptidyl peptidase-4 (DPP4) inhibitor or Glucagon-like peptide-1
             (GLP1) analogs during the past 3 months prior to admission.

          5. Acute critical illness or coronary artery bypass graft (CABG) surgery expected to
             require admission to a critical care unit.

          6. Subjects with gastrointestinal obstruction or adynamic ileus or those expected to
             require gastrointestinal suction.

          7. Patients with clinically relevant pancreatic or gallbladder disease.

          8. Patients with previous history of pancreatitis

          9. Patients with acute myocardial infarction, clinically significant hepatic disease or
             significantly impaired renal function (GFR &lt; 30 ml/min).

         10. Chronic use of steroid with total daily dose (prednisone equivalent) &gt;5 mg/day

         11. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

         12. Pregnancy or breast feeding at time of enrollment into the study.

         13. Patients who received supplemental sliding scale insulin &gt;72 hours prior to
             randomization

         14. Patients who received basal insulin &gt; 48 hours prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>May 8, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2018</results_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Linagliptin</keyword>
  <keyword>hospital hyperglycemia</keyword>
  <keyword>inpatient diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02004366/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between February 2014 and October 2016. Patients who participated in the in-hospital study period were invited to enroll in the prospective outpatient study. Of 250 in-patient participants, 224 accepted enrollment into outpatient study.</recruitment_details>
      <pre_assignment_details>Of the 295 subjects consented, there were 15 screen failures. 30 (out of remaining 280 patients) were excluded from participation: 11 patients stayed &lt;24 hours, 1 patient received corticosteroids, and 18 patients didn't receive medication. Therefore, 250 patients started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin In-hospital</title>
          <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="P2">
          <title>Basal Bolus In-hospital</title>
          <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="P3">
          <title>Linagliptin on Discharge</title>
          <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
        </group>
        <group group_id="P4">
          <title>Linagliptin+50%Glargine Dose on d/c</title>
          <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
        </group>
        <group group_id="P5">
          <title>Linagliptin+80%Glargine Dose on d/c</title>
          <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>In-hospital</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>On Discharge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants are represented for the two stages of the study (in-hospital and discharge), and are counted more than once in the Total.</population>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin In-hospital</title>
          <description>Linagliptin once daily+ correction doses of aspart or lispro if needed
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="B2">
          <title>Basal Bolus In-hospital</title>
          <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="B3">
          <title>Linagliptin on Discharge</title>
          <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
        </group>
        <group group_id="B4">
          <title>Linagliptin+50%Glargine Dose on d/c</title>
          <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
        </group>
        <group group_id="B5">
          <title>Linagliptin+80%Glargine Dose on d/c</title>
          <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="92"/>
            <count group_id="B4" value="93"/>
            <count group_id="B5" value="39"/>
            <count group_id="B6" value="474"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>In-hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="11"/>
                    <measurement group_id="B2" value="58" spread="12"/>
                    <measurement group_id="B3" value="NA" spread="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B4" value="NA" spread="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B5" value="NA" spread="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B6" value="57.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" spread="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B2" value="NA" spread="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B3" value="58.8" spread="10.0"/>
                    <measurement group_id="B4" value="57.1" spread="11.7"/>
                    <measurement group_id="B5" value="50.7" spread="11.5"/>
                    <measurement group_id="B6" value="56.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>In-hospital</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B4" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B5" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B6" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B4" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B5" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B6" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B2" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B2" value="NA">Arms are not relevant to the named period</measurement>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>In-hospital Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-hospital White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-hospital Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-hospital Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <title>In-hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discharged</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Glycemic Control</title>
        <description>Determine differences in glycemic control as measured by mean daily BG concentration between linagliptin alone and basal bolus therapy group.</description>
        <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Glycemic Control</title>
          <description>Determine differences in glycemic control as measured by mean daily BG concentration between linagliptin alone and basal bolus therapy group.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" spread="47"/>
                    <measurement group_id="O2" value="159" spread="41"/>
                    <measurement group_id="O3" value="126" spread="22"/>
                    <measurement group_id="O4" value="132" spread="28"/>
                    <measurement group_id="O5" value="142" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia &lt;70 mg/dl</title>
        <description>Subjects with Hypoglycemia &lt;70 mg/dl</description>
        <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia &lt;70 mg/dl</title>
          <description>Subjects with Hypoglycemia &lt;70 mg/dl</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperglycemia</title>
        <description>Subjects with BG &gt; 300 mg/dl</description>
        <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperglycemia</title>
          <description>Subjects with BG &gt; 300 mg/dl</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Dose of Insulin</title>
        <description>Total daily dose of insulin</description>
        <time_frame>Inpatient (average 5 days) and outpatient up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Dose of Insulin</title>
          <description>Total daily dose of insulin</description>
          <units>units/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.17"/>
                    <measurement group_id="O2" value="0.31" spread="0.15"/>
                    <measurement group_id="O3" value="0.23" spread="0.1"/>
                    <measurement group_id="O4" value="0.18" spread="0.1"/>
                    <measurement group_id="O5" value="0.24" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Length of hospital stay (ONLY for inpatient arms 1 and 2)</description>
        <time_frame>During Hospitalization</time_frame>
        <population>Length of hospital stay is applicable ONLY for inpatient arms (1 and 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Length of hospital stay (ONLY for inpatient arms 1 and 2)</description>
          <population>Length of hospital stay is applicable ONLY for inpatient arms (1 and 2)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring ICU Care During Hospitalization</title>
        <description>Need for intensive care unit (ICU) care (transfer to ICU) during hospitalization</description>
        <time_frame>During Hospitalization-average 5 days</time_frame>
        <population>Transfer to ICU is applicable ONLY for inpatient arms (1 and 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily+ correction doses of aspart or lispro if needed
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring ICU Care During Hospitalization</title>
          <description>Need for intensive care unit (ICU) care (transfer to ICU) during hospitalization</description>
          <population>Transfer to ICU is applicable ONLY for inpatient arms (1 and 2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Complications</title>
        <description>Subjects with composite complication (ONLY for inpatient arms 1 and 2)</description>
        <time_frame>During Hospitalization-average 5 days</time_frame>
        <population>Composite complication during hospitalization is applicable ONLY for inpatient arms (1 and 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Complications</title>
          <description>Subjects with composite complication (ONLY for inpatient arms 1 and 2)</description>
          <population>Composite complication during hospitalization is applicable ONLY for inpatient arms (1 and 2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Renal Failure During Hospitalization</title>
        <description>Subjects with Acute renal failure (ONLY for inpatient arms 1 and 2)</description>
        <time_frame>During Hospitalization-average 5 days</time_frame>
        <population>Acute renal failure during hospitalization is applicable ONLY for inpatient arms (1 and 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Renal Failure During Hospitalization</title>
          <description>Subjects with Acute renal failure (ONLY for inpatient arms 1 and 2)</description>
          <population>Acute renal failure during hospitalization is applicable ONLY for inpatient arms (1 and 2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality</title>
        <description>Hospital mortality (ONLY in-patient). Mortality is defined as death occurring during hospital stay.</description>
        <time_frame>During Hospitalization-average 5 days</time_frame>
        <population>Hospital mortality is applicable ONLY for inpatients arms (1 and 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <description>Hospital mortality (ONLY in-patient). Mortality is defined as death occurring during hospital stay.</description>
          <population>Hospital mortality is applicable ONLY for inpatients arms (1 and 2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting BG Concentration</title>
        <description>Average - per hospital stay - fasting BG concentration (for in-hospital groups), and average - per outpatient follow-up period - fasting BG concentration (for discharge groups)</description>
        <time_frame>During Hospitalization (average 5 days) and outpatient up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting BG Concentration</title>
          <description>Average - per hospital stay - fasting BG concentration (for in-hospital groups), and average - per outpatient follow-up period - fasting BG concentration (for discharge groups)</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="44"/>
                    <measurement group_id="O2" value="167" spread="44"/>
                    <measurement group_id="O3" value="125" spread="22"/>
                    <measurement group_id="O4" value="133" spread="27"/>
                    <measurement group_id="O5" value="141" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Wound and Other Infections</title>
        <description>Subjects with wound and other infections.</description>
        <time_frame>During Hospitalization and outpatient up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Wound and Other Infections</title>
          <description>Subjects with wound and other infections.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Level</title>
        <description>HbA1c level at admission (for in-patient arms) and HbA1c level at 12-week follow-up outpatient visit (for discharge arms).</description>
        <time_frame>Admission to the hospital and 12-week follow-up outpatient visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Level</title>
          <description>HbA1c level at admission (for in-patient arms) and HbA1c level at 12-week follow-up outpatient visit (for discharge arms).</description>
          <units>% DCCT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="1.9"/>
                    <measurement group_id="O2" value="8.0" spread="2.0"/>
                    <measurement group_id="O3" value="6.6" spread="0.8"/>
                    <measurement group_id="O4" value="7.0" spread="1.0"/>
                    <measurement group_id="O5" value="8.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia &lt; 40 mg/dl</title>
        <description>Subjects with Hypoglycemia &lt; 40 mg/dl</description>
        <time_frame>Inpatient and up to 12 weeks outpatient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia &lt; 40 mg/dl</title>
          <description>Subjects with Hypoglycemia &lt; 40 mg/dl</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Room Visits</title>
        <description>Number of ER visits ONLY for outpatient arms 3,4, and 5.</description>
        <time_frame>3 months after discharge</time_frame>
        <population>Emergency visits reported only for outpatient time. Inpatient (hospital) patients cannot have ER visits</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room Visits</title>
          <description>Number of ER visits ONLY for outpatient arms 3,4, and 5.</description>
          <population>Emergency visits reported only for outpatient time. Inpatient (hospital) patients cannot have ER visits</population>
          <units>Visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Surgical Reinterventions</title>
        <description>Subjects with surgical re-interventions.</description>
        <time_frame>Inpatient and up to 12 weeks outpatient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Surgical Reinterventions</title>
          <description>Subjects with surgical re-interventions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outpatient Mortality</title>
        <description>Deaths among patients after hospital discharge.</description>
        <time_frame>3 months after discharge</time_frame>
        <population>Deaths after hospital discharge are applicable ONLY for outpatient arms (3, 4 and 5).</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin In-hospital</title>
            <description>Linagliptin once daily+ correction doses of aspart or lispro if needed
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O2">
            <title>Basal Bolus In-hospital</title>
            <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin on Discharge</title>
            <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin+50%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
          </group>
          <group group_id="O5">
            <title>Linagliptin+80%Glargine Dose on d/c</title>
            <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Outpatient Mortality</title>
          <description>Deaths among patients after hospital discharge.</description>
          <population>Deaths after hospital discharge are applicable ONLY for outpatient arms (3, 4 and 5).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="93"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 weeks (average 5 days in hospital and 12 weeks after discharge)</time_frame>
      <desc>Adverse Events were monitored/assessed without regard to the specific Adverse Event Term</desc>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin In-hospital</title>
          <description>Linagliptin once daily + correction doses of aspart or lispro if needed.
Linagliptin: Linagliptin once daily + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="E2">
          <title>Basal Bolus In-hospital</title>
          <description>Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
Basal Bolus: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed</description>
        </group>
        <group group_id="E3">
          <title>Linagliptin on Discharge</title>
          <description>Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
Linagliptin: Patients with admission A1C &lt; 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.</description>
        </group>
        <group group_id="E4">
          <title>Linagliptin+50%Glargine Dose on d/c</title>
          <description>Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 50% Glargine dose on discharge: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.</description>
        </group>
        <group group_id="E5">
          <title>Linagliptin+80%Glargine Dose on d/c</title>
          <description>Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
Linagliptin + 80% Glargine: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ICU admission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Resurgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical Reintervention</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Priyathama Vellanki</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>priyathama.vellanki@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

